Skip to main content
SpringerLink
Log in

Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma

Expression von Aurora-B und FOXM1 prognostizieren schlechtes Überleben bei Patienten mit nasopharyngealem Karzinom

  • Original Article
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this work was to investigate the relationship between Aurora-B, FOXM1, and clinical outcomes in patients with nasopharyngeal carcinoma (NPC) who were treated with a combination of induction chemotherapy and radiotherapy.

Patients and methods

The expression of Aurora-B and FOXM1 were investigated by immunohistochemistry using a tissue microarray (TMA) containing samples from 166 NPC patients who were treated with cisplatin (DDP) + fluorouracil (5-FU) induction chemotherapy and radiotherapy between 1999 and 2005. The relationship of Aurora-B, FOXM1, and survival of these NPC patients was analyzed.

Results

Informative TMA results were obtained in 91 tumor cases for Aurora-B and 93 tumor cases for FOXM1. The 8-year failure-free survival rate (FFS) for the Aurora-B-negative and Aurora-B-positive group was 65.6 and 37.3 %, respectively (p = 0.024), and the 8-year distant FFS (D-FFS) rate was 65.6 and 41.5 %, respectively (p = 0.047). The 8-year overall survival (OS) in the FOXM1-negative group was moderately higher than in the FOXM1-positive group (58.4 vs 39.1 %, p = 0.081). Cox regression analysis revealed that for FFS, Aurora-B expression was a significant prognostic factor (p = 0.025), while for D-FFS, Aurora-B expression was a marginally significant prognostic factor (p = 0.056). When FOXM1 expression was analyzed, the Cox regression analyses showed that FOXM1 expression was a marginally significant prognostic factor (p = 0.056) for OS. Correlation analysis showed that Aurora-B and FOXM1 expression had no significant correlation.

Conclusion

Aurora-B and FOXM1 were both adverse prognostic markers for NPC patients treated with chemoradiotherapy. However, the two markers had no significant correlation.

Zusammenfassung

Ziel

Ziel war die Untersuchung der Beziehung zwischen Aurora-B, FOXM1 und den klinischen Ergebnissen bei Patienten mit nasopharyngealem Karzinom (NPC), die mit einer Kombinationstherapie aus Induktionschemotherapie und Radiotherapie behandelt wurden.

Patienten und Methoden

Die Expression von Aurora-B und FOXM1 wurde durch Immunohistochemie mittels Gewebemikroarray (TMA) mit Proben von 166 Patienten mit NPC durchgeführt, die zwischen 1999 und 2005 mit Cisplatin (DDP) + Fluorouracil-(5-FU-)Induktionschemotherapie und Radiotherapie behandelt worden waren. Die Beziehung von Aurora-B, FOXM1 und dem Überleben dieser Patienten mit NPC wurde analysiert.

Ergebnisse

Informative TMA-Ergebnisse zu Aurora-B wurden bei 91 Tumorpatienten und zu FOXM1 bei 93 Tumorpatienten erzielt. Die 8-Jahres-Überlebensrate ohne Therapieversagen (FFS, “failure-free survival”,) betrug in der Aurora-B-negativen Gruppe 65,6% und in der Aurora-B-positiven Gruppe 37,3% (p = 0,024). Die fernmetastasenfreie 8-Jahres-FFS-(D-FFS-)Rate betrug jeweils 65,6 bzw. 41,5% (p = 0,047). Das 8-Jahres-Gesamtüberleben (OS, “overall survival”) in der FOXM1-negativen Gruppe war mittelgradig höher als in der FOXM1-positiven Gruppe (58,4 vs. 39,1%; p = 0,081). Die Cox-Regressionsanalyse zeigte, dass die Aurora-B-Expression für das FFS ein signifikanter prognostischer Faktor war (p = 0,025); für das D-FFS war die Aurora-B-Expression ein geringfügig signifikanter prognostischer Faktor (p = 0,056). Bei der Analyse der FOXM1-Expression zeigten die Cox-Regressionsanalysen, dass die FOXM1-Expression ein geringfügig signifikanter prognostischer Faktor für OS war (p = 0,056). Die Korrelationsanalyse zeigte, dass die Aurora-B- und FOXM1-Expression nicht signifikant korreliert waren.

Schlussfolgerung

Aurora-B und FOXM1 waren beide ungünstige prognostische Marker für Patienten mit NPC, die mit Chemoradiotherapie behandelt wurden. Dennoch zeigten die beiden Marker keine signifikante Korrelation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Reference

  1. Razak AR, Siu LL, Liu FF et al (2010) Nasopharyngeal carcinoma: the next challenges. Eur J Cancer 46:1967–1978

    Article  PubMed  Google Scholar 

  2. Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62:672–679

    Article  PubMed  Google Scholar 

  3. Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61:1107–1116

    Article  PubMed  Google Scholar 

  4. Le QT, Tate D, Koong A et al (2003) Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 56:1046–1054

    Article  PubMed  Google Scholar 

  5. Lee N, Xia P, Quivey JM et al (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12–22

    Article  PubMed  Google Scholar 

  6. Baujat B, Audry H, Bourhis J et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47–56

    Article  CAS  PubMed  Google Scholar 

  7. Langendijk JA, Leemans CR, Buter J et al (2004) The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22:4604–4612

    Article  CAS  PubMed  Google Scholar 

  8. Mehra R, Serebriiskii IG, Burtness B et al (2013) Aurora kinases in head and neck cancer. Lancet Oncol 14:e425–e435

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842–854

    Article  CAS  PubMed  Google Scholar 

  10. Bonet C, Giuliano S, Ohanna M et al (2012) Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem 287:29887–29898

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Erpolat OP, Gocun PU, Akmansu M et al (2012) High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlenther Onkol 188:248–254

    Article  CAS  PubMed  Google Scholar 

  12. Tovuu LO, Utsunomiya T, Imura S et al (2014) The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma. Int J Clin Oncol 19:622–628

    Article  CAS  PubMed  Google Scholar 

  13. Takeshita M, Koga T, Takayama K et al (2013) Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer 80:85–90

    Article  PubMed  Google Scholar 

  14. Wang Y, Wu MC, Sham JS et al (2002) Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95:2346–2352

    Article  CAS  PubMed  Google Scholar 

  15. Liu ZG, Yi W, Tao YL et al (2012) Aurora-A is an efficient marker for predicting poor prognosis in human nasopharyngeal carcinoma with aggressive local invasion: 208 cases with a 10-year follow-up from a single institution. Oncol Lett 3:1237–1244

    PubMed Central  PubMed  Google Scholar 

  16. Qi G, Ogawa I, Kudo Y et al (2007) Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch 450:297–302

    Article  CAS  PubMed  Google Scholar 

  17. Vischioni B, Oudejans JJ, Vos W et al (2006) Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 5:2905–2913

    Article  CAS  PubMed  Google Scholar 

  18. Yasen M, Mizushima H, Mogushi K et al (2009) Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci 100:472–480

    Article  CAS  PubMed  Google Scholar 

  19. Chen YJ, Chen CM, Twu NF et al (2009) Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 455:431–440

    Article  CAS  PubMed  Google Scholar 

  20. Dees EC, Cohen RB, von Mehren M et al (2012) Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18:4775–4784

    Article  CAS  PubMed  Google Scholar 

  21. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  CAS  PubMed  Google Scholar 

  22. Yang J, Ikezoe T, Nishioka C et al (2007) AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 110:2034–2040

    Article  CAS  PubMed  Google Scholar 

  23. Mortlock AA, Foote KM, Heron NM et al (2007) Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 50:2213–2224

    Article  CAS  PubMed  Google Scholar 

  24. Jiang L, Wang P, Chen H (2014) Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma. Ups J Med Sci 119:324–332

    Article  PubMed Central  PubMed  Google Scholar 

  25. Chen H, Yang C, Yu L et al (2012) Adenovirus-mediated RNA interference targeting FOXM1 transcription factor suppresses cell proliferation and tumor growth of nasopharyngeal carcinoma. J Gene Med 14:231–240

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by National High Technology Research and Development Program of China (863 Program No. 2012AA02A501 and 2012AA02A206); Clinical Research of Special Funds of Wu Jieping Medical Foundation (No. 320.6750.14270).

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P.R. China

    Pei-Yu Huang, Yan Li, Dong-Hua Luo, Xue Hou, Ting-Ting Zeng, Meng-Qing Li, Hai-Qiang Mai M.D., PH.D. & Li Zhang M.D., PH.D.

  2. Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, 510060, Guangzhou, P.R. China

    Pei-Yu Huang, Dong-Hua Luo & Hai-Qiang Mai M.D., PH.D.

  3. Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, 510060, Guangzhou, P.R. China

    Xue Hou & Li Zhang M.D., PH.D.

Authors
  1. Pei-Yu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-Hua Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xue Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ting-Ting Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meng-Qing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hai-Qiang Mai M.D., PH.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Li Zhang M.D., PH.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hai-Qiang Mai M.D., PH.D. or Li Zhang M.D., PH.D..

Ethics declarations

Conflict of interest

P.-Y. Huang, Y. Li, D.-H. Luo, X. Hou, T.-T. Zeng, M.-Q. Li, H.-Q. Mai, and L. Zhang state that there are no conflicts of interest.

All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form). Informed consent was obtained from all patients included in studies

Additional information

Pei-Yu Huang and Yan Li contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, PY., Li, Y., Luo, DH. et al. Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma. Strahlenther Onkol 191, 649–655 (2015). https://doi.org/10.1007/s00066-015-0840-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-015-0840-4

Keywords

Schlüsselwörter

Search

Navigation